These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1382 related articles for article (PubMed ID: 31195981)

  • 1. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
    Long JK; Dai W; Zheng YW; Zhao SP
    Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circ_0057558 promotes nonalcoholic fatty liver disease by regulating ROCK1/AMPK signaling through targeting miR-206.
    Chen X; Tan QQ; Tan XR; Li SJ; Zhang XX
    Cell Death Dis; 2021 Aug; 12(9):809. PubMed ID: 34446693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
    Liu J; Tang T; Wang GD; Liu B
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
    [No Abstract]   [Full Text] [Related]  

  • 4. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload.
    Wang L; Sun M; Cao Y; Ma L; Shen Y; Velikanova AA; Li X; Sun C; Zhao Y
    Arch Biochem Biophys; 2020 Nov; 695():108642. PubMed ID: 33098868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA-141 is associated with hepatic steatosis by downregulating the sirtuin1/AMP-activated protein kinase pathway in hepatocytes.
    Yousefi Z; Nourbakhsh M; Abdolvahabi Z; Ghorbanhosseini SS; Hesari Z; Yarahmadi S; Ezzati-Mobasser S; Seiri P; Borji M; Meshkani R; Malek M
    J Cell Physiol; 2020 Feb; 235(2):880-890. PubMed ID: 31256424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
    Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
    Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
    Zhang J; Du H; Shen M; Zhao Z; Ye X
    J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
    Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
    Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
    Xiao Z; Chu Y; Qin W
    Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
    Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
    Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
    [No Abstract]   [Full Text] [Related]  

  • 13. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.
    Xiao J; Bei Y; Liu J; Dimitrova-Shumkovska J; Kuang D; Zhou Q; Li J; Yang Y; Xiang Y; Wang F; Yang C; Yang W
    J Cell Mol Med; 2016 Feb; 20(2):204-16. PubMed ID: 26648452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis.
    Simão AL; Afonso MB; Rodrigues PM; Gama-Carvalho M; Machado MV; Cortez-Pinto H; Rodrigues CMP; Castro RE
    J Mol Med (Berl); 2019 Aug; 97(8):1113-1126. PubMed ID: 31139863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
    Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
    Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6.
    Huang P; Huang FZ; Liu HZ; Zhang TY; Yang MS; Sun CZ
    Metabolism; 2019 May; 94():1-8. PubMed ID: 30711569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-Regulation of SIRT1 Expression by mir-23b Contributes to Lipid Accumulation in HepG2 Cells.
    Borji M; Nourbakhsh M; Shafiee SM; Owji AA; Abdolvahabi Z; Hesari Z; Ilbeigi D; Seiri P; Yousefi Z
    Biochem Genet; 2019 Aug; 57(4):507-521. PubMed ID: 30697640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
    Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
    Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1.
    Wang Y; Zhu K; Yu W; Wang H; Liu L; Wu Q; Li S; Guo J
    Biochem Biophys Res Commun; 2017 Nov; 493(1):227-232. PubMed ID: 28899784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ablation of systemic SIRT1 activity promotes nonalcoholic fatty liver disease by affecting liver-mesenteric adipose tissue fatty acid mobilization.
    Cheng J; Liu C; Hu K; Greenberg A; Wu D; Ausman LM; McBurney MW; Wang XD
    Biochim Biophys Acta Mol Basis Dis; 2017 Nov; 1863(11):2783-2790. PubMed ID: 28789977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.